Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage.
Wang H, Peng R, Wang J, Qin Z, Xue L. · 2018
Read Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. by Wang H, Peng R, Wang J, Qin Z, Xue L. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5913875.txt.
Description
Wang and co-authors review circulating microRNAs as possible cancer biomarkers. Their review appeared in Clinical Epigenetics. MicroRNAs are tiny non-coding RNAs that enter the blood. They stay stable there and shift in disease. Tumour biopsy and imaging have limits of harm and reach. Blood markers could catch cancer earlier and more gently.
These markers may aid diagnosis and tumour typing, they report. They may also track drug resistance and predict outcomes. Yet problems block routine clinical use so far. Reliability and standard methods still need work. Future studies must prove clear added value. Readers get both the promise and the drawbacks.
Catalog record
| CREATOR | Wang H, Peng R, Wang J, Qin Z, Xue L. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |